BACKGROUND: Although poor adherence to hormonal therapies such as aromatase inhibitors (AIs) is widely documented, to the authors' knowledge less is known regarding whether health beliefs predict treatment nonadherence. The objective of the current study was to evaluate the relationship between health beliefs (perceived susceptibility to breast cancer, perceived benefits of AI treatment, and perceived barriers to AI treatment) and adherence to AIs. METHODS: Postmenopausal women with early-stage, estrogen receptor-positive breast cancer who were currently receiving treatment with an AI completed the 3-factor Health Beliefs and Medication Adherence in Breast Cancer scale and questionnaires concerning their demographics and symptoms. Adherence data (treatment gaps and premature discontinuation) were abstracted from participants' medical charts. Logistic regression analyses were conducted to evaluate the relationship between health beliefs and adherence. RESULTS: Among 437 participants, 93 (21.3%) were nonadherent. Those who perceived greater barriers to their AI treatment were more likely to demonstrate AI nonadherence behaviors by the end of their treatment period compared with those who reported fewer barriers to AI therapy (adjusted odds ratio, 1.71; 95% confidence interval, 1.03-2.86 [P 5.04]). In contrast, perceived susceptibility to cancer recurrence and perceived benefits of AIs did not appear to predict AI adherence. Minority individuals were found to have lower perceived susceptibility to breast cancer recurrence and higher perceived barriers to AI treatment (P<.05 for both). Conclusions: Greater perceived barriers appeared to predict nonadherence to AIs. Interventions addressing women's negative beliefs regarding the challenges of AI treatment are needed to help optimize adherence in survivors of breast cancer. Cancer 2017;123:169-76.
INTRODUCTION
For many women with breast cancer, treatment does not end with chemotherapy, radiation, or surgery. After completing their primary treatments, survivors of hormone-dependent breast cancer are often prescribed oral adjuvant hormonal therapy, including selective estrogen receptor modulators (eg, tamoxifen or raloxifene) or aromatase inhibitors (AIs). For postmenopausal women, AIs are considered the front-line medication for preventing breast cancer recurrence. 1, 2 Despite the efficacy of AIs, many women do not fully adhere to their medication regimen and even discontinue treatment prematurely. A systematic review of adherence rates to endocrine therapy found that 9% to 50% of patients being treated with AIs were nonadherent. 3 The consequences of nonadherence can be devastating: Withdrawing AI treatment prematurely, as well as taking breaks from the treatment, have each been found to be associated with a higher risk of cancer recurrence and mortality. 4 Risk factors for AI nonadherence that have been investigated to date include demographic, cancer, and symptom variables, including race, age, educational level, income, cancer stage, joint pain, etc. 3, [5] [6] [7] [8] [9] Findings from this research have enhanced our understanding of which patients may be most likely to demonstrate nonadherence to AIs, but because many of these factors are not modifiable (such as age), or at least cannot be changed by the health care system (such as income), it is important to identify those factors on which clinicians can intervene.
One potentially modifiable factor that may play a role in predicting adherence to AIs is health beliefs. Three major components of the health belief model include perceived susceptibility, perceived benefits, and perceived barriers. 10 Each of these reflects key elements of the mental calculations an individual makes before taking action to avoid a negative health outcome. Some or all of these constructs have been shown to be associated with adherence behaviors among survivors of breast cancer. 11, 12 For example, survivors of breast cancer who perceive tamoxifen to have greater benefits than risks are more likely to adhere to their treatment than those who perceive the opposite. 12 However, to our knowledge, the relationship between health beliefs and AI adherence currently is unknown, and given that tamoxifen and AIs have different side effect profiles, it is reasonable to speculate that survivors may hold different beliefs regarding AIs. 13 In the current study, we hypothesized that survivors of breast cancer with greater perceived benefits of AIs, greater perceived susceptibility to breast cancer recurrence, and lower perceived barriers to treatment with AIs would be more likely to adhere to AIs. As a secondary aim, we also evaluated whether health beliefs differed by key demographic and medical variables.
MATERIALS AND METHODS
Participants were drawn from Wellness After Breast Cancer (WABC), an ongoing cohort study of postmenopausal survivors of breast cancer who had been prescribed AIs and provided informed consent between March 2008 and July 2009. 14 We chose this time frame to ensure all participants in this study had an opportunity to complete the 5 years of prescribed AI therapy. Inclusion criteria for WABC were as follows: 1) female sex; 2) age 18 years; 3) postmenopausal status; 4) stage I to III (TNM System), hormone receptor-positive breast cancer; 5) use of a thirdgeneration AI; 6) completion of all chemotherapy and/or radiotherapy at least 1 month before the survey date; and 7) the ability to provide informed consent in English. Recruitment took place at a breast cancer clinic at an academic teaching hospital. The study was approved by the Institutional Review Board of the University of Pennsylvania.
Analysis was focused on participants who were receiving an AI at the time of the survey (437 participants). Adherence outcome data and the majority of clinical variables were gathered from participants' medical charts. Other variables came from the WABC baseline survey that participants completed.
Measures

Adherence
Adherence information was abstracted from participants' medical charts. Oncology progress notes and telephone calls that dated from the day the participant completed the WABC survey to the end date of their prescribed AI treatment (typically 5 years) were searched for medication-related events. Treatment interruptions (defined as any time off AI therapy during the prescribed treatment) and premature discontinuation (defined as withdrawing from treatment with an AI entirely before the prescribed end date) were both considered forms of nonadherence and were grouped together into 1 binary outcome variable ("adherent" vs "nonadherent"). Discontinuations after breast cancer recurrence or metastasis were not considered nonadherence events.
Premature discontinuation and treatment interruptions were abstracted from the medical records. Raters were trained to do the abstractions on a different data set until they achieved strong interrater reliability with an experienced rater (kappa statistic, 0.70 for each category). Adherent behavior was coded as 0 and nonadherence was coded as 1. Subsequently, approximately 12.5% of cases were independently reabstracted by 1 of 2 additional raters; interrater reliability was good to excellent (0.78-1.00) for both categories of nonadherence.
Health beliefs
At the time of study entry, all participants completed the Health Beliefs and Medication Adherence in Breast Cancer (HBMABC) scale, a measure adapted from the Champion's Health Belief Model Scale for mammography screening (kindly provided with permission from Carrie Stricker). Each item consists of a Likert-type scale ranging from 1 (indicating strongly disagree) to 5 (indicating strongly agree). To determine the factor structure of the scale, we randomly split the sample into 2 and conducted an exploratory factor analysis (promax rotation) using the first subsample. We followed this with a confirmatory factor analysis to determine whether the solution from the exploratory analysis fit the data for the second subsample.
For the exploratory factor analysis, the pattern of factor loadings as well as the scree plot of Eigenvalues indicated a 3-factor solution. Three items were deleted due to a lack of salience (factor loading < 0.4) or because when they were removed, the internal consistency of the subscales improved. Factor loadings and communalities are shown in Table 1 . The 3 factors identified mapped onto the theoretical constructs that informed the development of the HBMABC: perceived susceptibility, Original Article perceived benefits, and perceived barriers. Within the context of AIs, susceptibility reflected a survivor's sense of vulnerability to breast cancer recurrence, perceived benefits represented a survivor's beliefs about the efficacy of AIs, and perceived barriers captured the difficulties survivors believe they face in adhering to their AI treatment.
For the confirmatory factor analysis, we examined multiple indices to determine the goodness of fit of the 3-factor solution for the second subsample: the chi-square/ degrees of freedom ratio, the comparative fit index, the Tucker-Lewis index, and the root mean square error of approximation. The results indicated that the factor structure had a reasonable fit to the data (chi-square/degree of freedom ratio, 2.13; comparative fit index, 0.98; TuckerLewis Index, 0.98; and root mean square error of approximation, 0.07 [90% confidence interval (90% CI), 0.06-0.9]). 15 Cronbach alphas for the 3 subscales (using the entire sample) were .87 for perceived susceptibility, .77 for perceived benefits, and .83 for perceived barriers. The full range of scores was represented on both the perceived susceptibility and perceived benefits subscales (both [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] and on the perceived barriers subscale . Two of the 3 subscales were highly skewed, and therefore all subscales were dichotomized into low and high categories using a median split. A score of 8 (out of 15) on the perceived susceptibility subscale indicated low perceived susceptibility to cancer recurrence, a score of 11 (out of 15) on the perceived benefits subscale indicated low perceived benefits to AIs, and a score of 12 (out of 40) on the perceived barriers subscale indicated low perceived barriers to AI treatment.
Covariates Race, age, educational level, marital status, joint pain, clinical comorbidities, and date of last menstrual period were collected via self-report. Joint pain was measured with the worst pain item of the pain intensity subscale of the Brief Pain Inventory. This single item has been found to predict premature discontinuation among survivors of breast cancer who are receiving treatment with AIs. 7 Clinical variables, including cancer stage and prior use of tamoxifen, were abstracted from medical charts.
Statistical Analyses
Univariate analyses using logistic regression were conducted to assess the association between each variable and nonadherence. Univariately significant variables (P<.10) were assessed in multivariable logistic regression analyses. Chi-square tests were conducted to determine the relationship between health beliefs and demographic, medical, and psychosocial variables. All tests were 2-sided with P<.05 indicating statistical significance. A total of 24 participants were lost to follow-up and therefore we were unable to obtain information regarding their adherence behaviors. Data for these individuals were imputed using multiple imputation. SPSS statistical software (version 22; IBM Corporation, Armonk, NY) was used for all data analysis.
Power analysis
A power analysis using G*Power 16 demonstrated that with a sample of 437 participants, we had 80% power to detect an odds ratio (OR) of 1.91 assuming 30% of the sample was nonadherent and that each health beliefs subscale was moderately associated with covariates in the model. The nonadherence rate of 30% was selected based on rates observed in the literature. 3 
RESULTS
Participant Characteristics
Of the 437 participants, 82.6% were white, 14.9% were African American, 1.6% were Asian, and 0.9% classified themselves as "other." The sample of participants was highly educated: 35.1% had a graduate or professional degree, 43.6% attended at least some college, and 21.3% had a high school diploma or less. The majority of the participants were married or living with a partner (62.6%), and greater than one-half of the sample had been in a postmenopausal state for >10 years ( Table 2) .
Predictors of Nonadherence
Using multiple imputation, we estimated that a total of 93 participants (21.3%) exhibited some form of nonadherence after completing the survey. Of the 3 health belief subscales, perceived barriers was the only subscale that was found to be significantly associated with nonadherence. Those who reported having more barriers to AI treatment were more likely to later demonstrate nonadherence to AIs (25.7% vs 16.3%; P 5 .02) (Fig. 1) . In univariate analyses, joint pain and years receiving treatment with an AI at the time of the survey were found to be associated with premature discontinuation (Table 2 ). After we included joint pain and time receiving an AI in the model, perceived barriers remained a statistically significant predictor of nonadherence (adjusted OR, 1.71; 95% CI, 1.03-2.86 [P 5 .04]) (Table 3) , whereas joint pain was no longer statistically significant (adjusted OR, 1.48; 95% CI, 0.89-2.46 [P 5 .14]).
The barriers subscale included items regarding financial barriers, side effects, difficulty obtaining medicine refills, and other topics. Exploratory analyses were conducted to examine whether any particular items on the perceived barriers subscale drove the relationship between perceived barriers and adherence. When each item was examined independently, with joint pain severity and length of time receiving an AI included in the model, it was found that item 4 ("I have to take my AI for too many . Survivors who perceived that their pain made taking AIs difficult or that AI treatment lasted too long were more likely to demonstrate some form of nonadherence. To determine the degree to which item 5 and the joint pain item were measuring overlapping constructs, we assessed their correlation and found it to be modest (correlation coefficient, 0.32; P<.001).
Correlates of Health Beliefs
Women who had lower perceived susceptibility to cancer recurrence were more likely to be nonwhite (P 5 .01). Survivors who perceived less benefits to AI therapy were Abbreviations: %H, percentage of participants scoring below the median on a particular health beliefs subscale; %L, percentage of participants scoring above the median on a particular health beliefs subscale; BPI, Brief Pain Inventory; LMP, last menstrual period.
more likely to be aged >55 years (P 5 .003) and to have had more years in menopause (P 5 .009). Participants with higher perceived barriers to AI treatment were more likely to be nonwhite (P 5 .004) and to have higher joint pain levels (P 5 .004) ( Table 4) .
DISCUSSION
To achieve optimal clinical outcomes for survivors of breast cancer, adherence to AI therapy is essential. 17 In the current prospective cohort study, we found that participants who perceived greater barriers to AI treatment, as measured by the HBMABC, were more likely to later take breaks from their AI or stop taking it all together. Conversely, perceived susceptibility to breast cancer and perceived benefits of AIs were not found to be predictive of adherence. It is important to note that health beliefs were found to differ by sociodemographic characteristics, with minority women perceiving less risk of breast cancer recurrence as well as greater perceived barriers to AI treatment.
The findings of the current study are particularly important for several reasons. To the best of our knowledge, the current study is one of the first to identify a potentially modifiable psychological predictor of AI nonadherence; addressing women's perceptions of perceived barriers may help to improve their adherence to AIs. These findings also corroborate earlier work that has demonstrated that it may not be worth targeting perceived benefits to improve AI adherence. An intervention aimed at increasing patients' knowledge regarding the importance and benefits of AIs was found to have no significant impact on adherence rates. 18 Although it could be that the particular intervention that was implemented was not effective, it appears that survivors who are no longer willing to take AIs are not basing their decision on whether they believe AIs are effective; the results of the current study demonstrate that perceived barriers rather than perceived benefits were predictive of nonadherence. This is in contrast to tamoxifen adherence, for which beliefs regarding benefits have been shown to be associated with adherence in an observational study. 12 These findings suggest that the psychological determinants of adherence to tamoxifen and AIs may be different and underscore the importance of studying them as separate outcomes.
The role of pain perception emerged as an important element in the current study findings. Prior literature has shown that joint pain is a predictor of adherence to AIs. 7 However, in the current analysis, joint pain was no longer found to be predictive of adherence when pain beliefs were included in the model. In addition, pain beliefs and pain intensity were found to be only moderately correlated, suggesting that beliefs participants held about pain as a barrier to AI treatment were not completely tied to the degree of pain the participant experienced. These findings suggest that cognitions regarding the experience of pain, as opposed to pain itself, drive adherence behavior. Further research is needed to understand the psychological reactions of women to AI-associated joint pain. Prior work among other patient populations has demonstrated that fear of pain, for example, is a powerful predictor of behavior [19] [20] [21] ; women who experience greater distress due to pain anticipation may consider AIs more difficult to take. There may be other cognitions triggered by joint pain that are unique to the AI experience that lead to nonadherence. Understanding these reactions is important for the development of intervention content.
Patients' perceptions that AI treatment is too long also were found to be a barrier to adherence. This perception may reflect ambivalence regarding whether the benefits of AIs are worth the many years of side effects. Motivational interviewing, which can be delivered as a brief, short-term intervention, has been found to be effective at overcoming patients' ambivalence regarding making changes to their daily behaviors, 22 and may be effective at promoting AI adherence. In addition, because interventions have been shown to help with AI-related joint pain, 23, 24 health care providers should work with patients to detect the side effects of AIs early in treatment and engage patients in the management of their symptoms.
To our knowledge, the HBMABC is the first instrument to evaluate health beliefs related to AI therapy. The psychometric analyses herein support the original factor structure of the health belief model. In addition, we found that health beliefs are associated with several demographic and medical variables. Minority individuals and those with higher levels of joint pain tended to perceive greater barriers to their AI treatment. Although nonwhite individuals are no more likely to discontinue AI treatment than white individuals, previous work has shown that nonwhite individuals are less likely to initiate AI treatment. 25, 26 Several factors have been examined to explain these differences, including lower rates of insurance coverage and a higher presence of comorbidities among minority patients, but to our knowledge none has been found to fully explain racial disparities in AI initiation. 26 Health beliefs may help to shed light on what is driving poorer rates of AI initiation among minority individuals compared with white individuals and should be explored in future research.
Original Article
There are several limitations to the current study. Our measurement of adherence was based on abstracting information from notes in participants' medical records. This process relies on the reports of both participants and their physicians, which may not always be accurate due to recall and response biases. In addition, due to power considerations, we combined premature discontinuation and treatment interruptions into 1 outcome, although it is possible that each type of nonadherence is caused by a different psychological process. This is a topic that requires further research.
There also are several limitations to the current study due to the timing of the health beliefs assessments. All women included herein had been receiving an AI for at least 1 month when they consented to the study. Therefore, we were unable to study how health beliefs predict AI initiation and nonadherence within the first month of AI use. In addition, women provided informed consent to the study at different points in their AI treatment. Thus, women who discontinued the AI shortly after initiating treatment were underrepresented in the current study sample given that they had to be receiving an AI at the survey date to be included in the current analyses. It is possible that for these women, the psychological determinants of nonadherence were different from those of women who discontinued AI therapy later in treatment. It also is unclear whether participants' prior adherence behaviors may have impacted their health beliefs, thereby complicating our ability to interpret the direction of the relationship between health beliefs and adherence. A longitudinal study examining health beliefs at the beginning of treatment and at multiple time points over the course of treatment is needed to assess this possibility. Another limitation to the current study is that we controlled for joint pain severity but not other side effects. Last, the current study was conducted in an academic cancer center, thereby limiting its generalizability.
Conclusions
We found that the beliefs of survivors of breast cancer regarding barriers to treatment predicted their AI adherence. Beliefs regarding AI-related pain and treatment length appeared to be the most salient barriers. Incorporating health beliefs into research and clinical practice may help to elucidate the challenges patients face in both the initiation and continued use of AIs, and help to optimize clinical outcomes.
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